Established partnership with Kelun-Biotech expanding pipeline and accelerating combination strategy with CR-001, PD-1 x VEGF bispecific antibody, and multiple ADCs ASCEND Phase 1/2 global clinical trial underway to evaluate CR-001 in advanced solid tumors with three additional clinical trials across the portfolio expected to initiate in 2026 Completed $185 million private placement, supporting several key clinical data readouts beginning in Q1 2027 and providing expected cash runway into 2028 WALTHAM, Mass ...

Summary of Sichuan Kelun-Biotech Biopharmaceutical FY Conference Company Overview - **Company Name**: Sichuan Kelun-Biotech Biopharmaceutical (SEHK:06990) - **Industry**: Biopharmaceuticals - **Focus Areas**: Research, development, manufacturing, and commercialization of novel drugs in oncology, immunology, metabolism, and other therapeutic areas [2][3] Key Points Pipeline and Product Development - **Pipeline Programs**: Over 30 pipeline programs, including four approved products with seven indications, two products at NDA stage, and over 10 in clinical development [3] - **Employee Count**: Approximately 2,000 employees, with 900 in R&D, 500 in manufacturing and quality control, and 500 in sales and marketing [3] - **Approved Products**: - TROP2 ADC (SAC-TMT) approved for three indications in China, including lung cancer [4] - HER2-ADC (trastuzumab botidotecan) approved for HER2-positive breast cancer [4] - Cetuximab N01 for RAS wild-type colorectal cancer and PD-L1 for nasopharyngeal carcinoma [4] Clinical Studies and Results - **Clinical Trials**: Five pivotal studies initiated for breast cancer, six for lung cancer, and one for gastrointestinal cancer [5] - **Study Presentations**: Clinical data presented at major conferences, including ESMO and published in journals like the New England Journal of Medicine [6] - **Efficacy Data**: SAC-TMT demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) in various cancer types [10] Strategic Collaborations - **Partnerships**: Collaborations with MSD, Ellipses Pharma, and others to enhance pipeline value and global market reach [7][8] - **Out-License Agreements**: Entered into agreements to develop and commercialize novel oncology therapies [8] Market Position and Future Plans - **Market Access**: Three core products included in the National Reimbursement Drug List (NRDL) effective January 2026 [7] - **Commercialization Strategy**: Full-fledged commercialization team established, focusing on Class III hospitals and key opinion leaders [6] - **Growth Plans**: Focus on advancing differentiated pipeline programs, optimizing ADC platform, and expanding capabilities for drug development and commercialization [15][16] Innovation and Technology - **OptiDC Platform**: A world-class drug-conjugate technology platform aimed at optimizing drug design for better efficacy and safety [2][13] - **Non-Oncology Applications**: Exploring ADCs for autoimmune and metabolic diseases, combining biologicals and small molecules [14][15] Additional Insights - **Market Trends**: The company is positioned to leverage its innovative drug development capabilities in a rapidly evolving biopharmaceutical landscape, particularly in oncology [2][15] - **Regulatory Environment**: The inclusion of products in the NRDL indicates a supportive regulatory environment for biopharmaceuticals in China [7] This summary encapsulates the key aspects of the conference, highlighting the company's strategic direction, product pipeline, and market positioning within the biopharmaceutical industry.

Core Viewpoint - Apollomics Inc. reported its financial results for the first half of 2025, highlighting a significant reduction in net loss compared to the same period in 2024, alongside ongoing development of its oncology drug candidates [1][7]. Financial Performance - Cash, cash equivalents, bank deposits, and money market funds as of June 30, 2025, were $2.1 million, down from $9.8 million as of December 31, 2024 [7]. - Research and development (R&D) expenses for the first half of 2025 were $4.6 million, a decrease from $16.9 million in the first half of 2024 [7]. - General and administrative (G&A) expenses were $14.5 million for the first half of 2025, compared to $10.2 million in the same period of 2024 [7]. - The net loss for the first half of 2025 was $(12.5) million, or $(11.37) per basic and diluted share, compared to a net loss of $(35.2) million, or $(37.53) per basic and diluted share, for the first half of 2024 [7][14]. Asset and Liability Overview - Total assets as of June 30, 2025, were $11.1 million, down from $13.1 million as of December 31, 2024 [10]. - Current liabilities increased to $10.5 million as of June 30, 2025, from $7.4 million as of December 31, 2024 [10]. - The company reported net liabilities of $(4.4) million as of June 30, 2025, compared to net assets of $4.9 million at the end of 2024 [11]. Company Overview - Apollomics Inc. is focused on developing oncology therapies, with its lead program being vebreltinib (APL-101), a selective c-Met inhibitor currently in a Phase 2 clinical trial [3].

Core Insights - Crescent Biopharma is advancing its pipeline of next-generation therapeutics for solid tumors, with significant progress expected in the coming years [2][3] Pipeline Developments - CR-001, a PD-1 x VEGF bispecific antibody, is on track for an IND submission in the fourth quarter of 2025, with a global Phase 1 trial planned to start in early 2026 [1][6] - Preclinical data for CR-001 shows cooperative pharmacology and in vivo anti-tumor activity, with initial clinical data anticipated in the second half of 2026 [2][6] - CR-002 and CR-003, novel antibody-drug conjugates (ADCs), are expected to have an IND submission in mid-2026 [4][2] Financial Performance - As of September 30, 2025, Crescent Biopharma reported a cash position of $133.3 million, which is projected to fund operations through 2027 [5][13] - Research and development expenses for Q3 2025 were $20.3 million, while general and administrative expenses were $5.5 million [5][11] - The net loss for the third quarter of 2025 was $24.6 million, equating to a loss of $1.27 per share [7][11]

Core Insights - Secura Bio, Inc. is participating in the Jefferies Global Healthcare Conference from November 17 to 20, 2025, in London, UK, with CEO Chip Romp and CFO Will Brown attending [1]. Company Overview - Secura Bio is an integrated, commercial-stage pharmaceutical company focused on the development and commercialization of impactful oncology therapies for healthcare providers and patients [2]. Investor and Media Contacts - Will Brown serves as the Chief Financial Officer and can be contacted at 619-986-1364 or via email at ir@securabio.com for investor inquiries [3]. - Media inquiries can be directed to Kit Rodophele at Ten Bridge Communications, reachable at 617-999-9620 or krodophele@tenbridgecommunications.com [3].

Core Insights - Citius Oncology is transitioning from a development-stage company to a commercial-stage organization following the FDA approval of its drug LYMPHIR, aimed at treating cutaneous T-cell lymphoma [2][3] - The company is focused on disciplined capital deployment and operational execution to support the U.S. launch of LYMPHIR, while also seeking additional capital to enhance financial flexibility [3][4] Financial Results - As of March 31, 2025, Citius Oncology had $112 million in cash and cash equivalents, with a total of 71,552,402 common shares outstanding [5] - Research and Development (R&D) expenses for Q2 2025 were $3.1 million, up from $1.3 million in Q2 2024, primarily due to costs associated with drug substance batch expenses [6] - General and Administrative (G&A) expenses increased to $2.2 million in Q2 2025 from $1.4 million in Q2 2024, driven by pre-commercial and commercial launch activities for LYMPHIR [7] - The net loss for Q2 2025 was $7.7 million, or ($0.11) per share, compared to a net loss of $4.8 million, or ($0.07) per share, in Q2 2024 [9] Market Position and Strategy - LYMPHIR, approved in August 2024, targets a market estimated to exceed $400 million, which is currently underserved by existing therapies [11] - The company is engaging in discussions with potential commercial and strategic partners to secure additional capital and maximize stockholder value [3][4]

Core Viewpoint - Black Diamond Therapeutics reported strong financial results for Q1 2025, highlighting a significant net income and a robust cash position, while advancing its clinical trials for BDTX-1535 and BDTX-4933 [1][15]. Corporate Developments - The company is executing enrollment in the Phase 2 trial for BDTX-1535 targeting newly diagnosed patients with EGFRm NSCLC, with a clinical update expected in Q4 2025 [2][6]. - A global licensing agreement with Servier for BDTX-4933 was announced, providing an upfront payment of $70 million and potential milestone payments up to $710 million, along with tiered royalties based on global net sales [4][8]. Financial Highlights - As of March 31, 2025, Black Diamond had cash, cash equivalents, and investments totaling $152.4 million, a significant increase from $98.6 million at the end of 2024, which is expected to fund operations into Q4 2027 [6][10]. - The company reported a net income of $56.5 million for Q1 2025, compared to a net loss of $18.2 million for the same period in 2024 [15][19]. - Research and development expenses decreased to $10.5 million in Q1 2025 from $13.5 million in Q1 2024, attributed to workforce efficiencies [8][9]. Clinical Developments - Initial Phase 2 clinical data for BDTX-1535 in newly diagnosed patients with non-classical EGFRm NSCLC is expected to be disclosed in Q4 2025 [7]. - The Phase 0/1 trial of BDTX-1535 was expanded into newly diagnosed glioblastoma patients with EGFR alterations, showing promising pharmacokinetic and safety data [6][7].

Core Insights - Relmada Therapeutics has reported positive initial Phase 2 proof-of-concept data for NDV-01, showing a 90% overall response rate in non-muscle invasive bladder cancer (NMIBC) [1][4] - The company plans to initiate a Phase III registration trial for NDV-01 in the first half of 2026 and a Phase 2 study for sepranolone in Prader-Willi syndrome in the same timeframe [1][4] Pipeline Highlights - **NDV-01**: A sustained-release intravesical formulation of gemcitabine and docetaxel targeting high-grade NMIBC with a U.S. market opportunity of approximately 600,000 prevalent cases. The recent data shows a 90% overall response rate and 100% complete response in carcinoma in situ [5][10] - **Sepranolone**: A first-in-class GABAA Modulating Steroid Antagonist targeting disorders linked to excess GABAergic activity, with an estimated U.S. prevalence of 20,000 patients for Prader-Willi syndrome. A Phase 2 study is being prepared for initiation [5][11] Financial Results - For Q1 2025, the company reported a net loss of $17.5 million or $0.58 per share, compared to a net loss of $21.8 million or $0.72 per share in Q1 2024 [14][21] - Research and development expenses were $11.9 million, down from $13.3 million in Q1 2024, reflecting reduced trial costs [14][20] - Cash, equivalents, and short-term investments totaled $27.1 million as of March 31, 2025, down from $44.9 million at year-end 2024 [14][18]

Table of Contents As filed with the U.S. Securities and Exchange Commission on July 7, 2023. Registration Statement No. 333-272552 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Apollomics Inc. (Exact Name of Registrant as Specified in Its Charter) Not Applicable (Translation of Registrant's name into English) (State or Other Jurisdiction of Incorporation or Organization) Cayman Islands 2834 Not Appl ...